How effective is risk-reducing endocrine therapy for lobular carcinoma in situ?

LCIS is an abnormal change in the milk-producing lobules and a marker of increased risk in both breasts; it is not the same as an invasive breast cancer. Endocrine therapy lowers stimulation from hormones, so its potential benefit is greatest for cancers that respond to those hormones. It does not erase LCIS or guarantee that another type of breast cancer cannot develop.

The choice depends on menopause status, other health conditions, bone health, medicines, and how you weigh preventive benefit against side effects. Symptoms can include hot flushes, joint or muscle discomfort, menstrual changes, and sexual-health changes, depending on the treatment.

Discuss the option with a breast specialist who knows your biopsy findings and family history. Confirm whether your LCIS was classic or had other features, what imaging schedule is appropriate, and whether a different prevention strategy would suit you better.

Take the medicine exactly as prescribed if you choose it, and tell the team about new symptoms rather than quietly stopping. Regular clinical review helps assess tolerance and keeps screening on track.

Arrange prompt assessment for a new breast or underarm lump, bloody nipple discharge, nipple inversion, skin dimpling, or a persistent localised breast change. Seek urgent care for severe breathlessness, chest pain, coughing blood, or sudden swelling and pain in one leg.

How does my LCIS pattern affect the expected benefit? Which medicine fits my menopause status and bone health? What side effects should I report, and what breast examination and imaging plan will I follow?